Salt Lake City, UT (PRWEB) July 24, 2013
TFX Health, LLC announced earlier this week that its popular joint health supplement TFX Flex™ is now available at the online supplement retailer LuckyVitamin.com. In addition to several important vitamins and joint health nutrients, TFX Flex™ contains a breakthrough new dietary ingredient known as UC-II® that has been proven in human clinical studies to be 2X more effective than Glucosamine & Chondroitin for joint pain relief.
According to a TFX Health company spokesman, “LuckyVitamin.com is an important online outlet for health and wellness products and it provides another channel for those seeking new and improved solutions to joint health problems.” In addition to LuckyVitamin.com, TFX Flex™ is also available at GNC, Amazon, and other online and retail distribution channels. Since its launch earlier this year, TFX Flex™ has become GNC’s best-selling triple threat product for bone, joint, and muscle health.
The launch of TFX Flex™ quickly captured the attention of the joint health industry after glucosamine & chondroitin came under fire in a 2010 study published in the British Medical Journal. The study concluded that, “Glucosamine and Chondroitin, either taken together or separately, have not shown a clinically significant improvement in joint pain relief for patients troubled with knee or hip osteoarthritis [Wandel S, Juni P, Tendal B, et al. British Medical Journal Sept 16, 2010; 341:c4675]. The author of the study stated that, “Our findings indicate that glucosamine, chondroitin, and their combination do not result in a relevant improvement in joint pain relief compared with placebo.”
Worldwide annual sales of glucosamine & chondroitin have been estimated at more than $2 billion, with nearly half of that coming from the United States. A spokesman for TFX Health explained, “The science behind joint health is changing and consumers are actively looking for better alternatives to glucosamine & chondroitin. TFX Flex™ has been shown in human clinical studies to be 2X more effective than glucosamine & chondroitin and it is the only product on the market that takes an overall approach to bone, muscle, and joint health.
TFX Flex™ contains a breakthrough new dietary ingredient known as UC-II® Undenatured Type II Collagen that has been proven in human clinical studies to be 2X more effective than Glucosamine & Chondroitin for joint pain relief. UC-II® was developed by a team of scientists with more than 25 years of experience in the development of patented, clinically substantiated dietary ingredients. The new ingredient holds 7 international and U.S. patents and is supported by 9 human clinical studies, including research at Harvard Medical School.
In a randomized, double-blind, placebo-controlled human clinical study published in the International Journal of Medical Sciences it was found that only 40 mg of UC-II® was more than two times as effective as 1,500 mg of glucosamine and 1,200 mg of chondroitin in supporting joint health, comfort and flexibility. It outperformed the glucosamine & chondroitin combination in three different joint pain relief assessment tools: WOMAC, VAS and the Lequesne Functional Index. UC-II® significantly decreased joint pain during daily activities, including walking on a flat surface, performing heavy domestic duties, ascending stairs and while resting in bed. UC-II® was also shown to be safe and well tolerated with no known side effects [Crowley DC, Lau FC, Sharma P, et al. Int J Med Sci. 2009; 6:312-321].
About TFX Health, LLC
Based in Salt Lake City, TFX Health, LLC is an innovative pioneer in the development of advanced health and wellness products. Its brands include TFX Flex™ Joint Health Supplement, TFX Drive™ Testosterone Booster, TFX Elite™ Extreme Thermogenic, and other high end formulations. TFX Health products are manufactured in the USA in FDA registered, GMP compliant facilities and sold worldwide through online and traditional retail channels.
UC-II® is a trademark of InterHealth N.I. Clinical data available upon request. U.S. Patents 5,645,851; 5,637,321; 5,529,786; 5,750,144; 7,083,820; 7,846,487, EPO Patent 1435906B1 and worldwide patents pending.